Table 1. Basic characteristics, local and systemic treatments.
| Variable | Value |
|---|---|
| Age, median [range] (years) | 55.5 [34–78] |
| Gender (%) | |
| Males | 27 (67.5) |
| Females | 13 (32.5) |
| ECOG (%) | |
| 0 | 12 (30.0) |
| 1 | 23 (57.5) |
| 2 | 1 (2.5) |
| 3 | 0 |
| 4 | 2 (5.0) |
| N/A | 2 |
| Primary tumor location (%) | |
| Colon | 19 (47.5) |
| Rectum | 20 (50.0) |
| N/A | 1 |
| Primary resection at presentation (%) | |
| Yes | 28 (70.0) |
| No | 11 (27.5) |
| N/A | 1 |
| Nodal status at presentation (%) | |
| Positive | 21 (52.5) |
| Negative | 8 (20.0) |
| N/A | 11 |
| KRAS status (%) | |
| Exon 2 mutation | 11 (27.5) |
| Wild-type | 12 (30.0) |
| N/A | 17 |
| Grade (%) | |
| Low | 1 (2.5) |
| Moderate | 20 (50.0) |
| High | 7 (17.5) |
| N/A | 12 |
| LVI (%) | |
| Positive | 9 (22.5) |
| Negative | 9 (22.5) |
| N/A | 22 |
| PVI (%) | |
| Positive | 9 (22.5) |
| Negative | 8 (20.0) |
| N/A | 23 |
| CEA, median (range) (ng/mL) | 8.3 (0–6,000) |
| Metastatic at presentation (%) | 22 (55.0) |
| Site of metastasis (%) | |
| Liver | 19 (47.5) |
| Lung | 30 (75.0) |
| Bone | 11 (27.5) |
| Other | 8 (20.0) |
| None | 4 |
| Chemotherapy before BM (%) | |
| Oxaliplatin | 8 (20.0) |
| Irinotecan | 0 |
| Both | 22 (55.0) |
| None | 10 (25.0) |
| Biologics before BM (%) | |
| Anti-VEGF | 14 (37.8) |
| Anti-EGFR | 4 (10.8) |
| Both | 5 (12.5) |
| None | 16 (42.5) |
| Location of BM (%) | |
| Supratentorial | 18 (42.5) |
| Infratentorial | 8 (22.5) |
| Both | 11 (27.5) |
| N/A | 3 |
| Number of BM, median [range] | 2 [1–7] |
| RPA (%) | |
| 1 | 3 (7.5) |
| 2 | 33 (82.5) |
| 3 | 3 (5.0) |
| N/A | 2 |
| Local treatment of BM (%) | |
| Radiation alone | 26 (65.0) |
| Surgery alone | 2 (5.0) |
| Both | 9 (22.5) |
| None | 1 |
| N/A | 2 |
| Chemotherapy after BM (%) | |
| Oxaliplatin | 1 (2.7) |
| Irinotecan | 5 (13.5) |
| Both | 3 (8.1) |
| None | 28 (75.7) |
| Biologics after BM (%) | |
| Anti-VEGF | 3 (7.5) |
| Anti-EGFR | 1 (2.5) |
| Both | 3 (7.5) |
| None | 33 (82.5) |
BM, brain metastasis; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; EGFR, epithelial growth factor receptor; LVI, lymphovascular invasion; PVI, perineural invasion; RPA, recursive partitioning analysis; VEGF, vascular endothelial growth factor; N/A, not available.